Zonisamide: A review of the clinical and experimental evidence for its use in Parkinson′s disease
Authors:
Open Access
- 1 January 2013
- journal article
- review article
- Published by Medknow in Indian Journal of Pharmacology
- Vol. 45 (6) , 547-55
Abstract
The Indian Journal of Pharmacology is an official organ of the Indian Pharmacological SocietyKeywords
This publication has 52 references indexed in Scilit:
- Classic and New Animal Models of Parkinson's DiseaseJournal of Biomedicine and Biotechnology, 2012
- The role of calcium and mitochondrial oxidant stress in the loss of substantia nigra pars compacta dopaminergic neurons in Parkinson's diseaseNeuroscience, 2011
- Zonisamide-induced long-lasting recovery of dopaminergic neurons from MPTP-toxicityBrain Research, 2011
- Interactions of Monoamine Oxidases with the Antiepileptic Drug Zonisamide: Specificity of Inhibition and Structure of the Human Monoamine Oxidase B ComplexJournal of Medicinal Chemistry, 2010
- Parkinson's disease, primates, and gene therapy: Vive la différence?Movement Disorders, 2010
- Reliability in the Identification of Midbrain Dopamine NeuronsPLOS ONE, 2010
- Tyrosinase-Expressing Neuronal Cell Line as in Vitro Model of Parkinson’s DiseaseInternational Journal of Molecular Sciences, 2010
- The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: Clinical relevanceExperimental Neurology, 2010
- A molecular basis for the increased vulnerability of substantia nigra dopamine neurons in aging and Parkinson's diseaseMovement Disorders, 2010
- Dopamine and impulse control disorders in Parkinson's diseaseAnnals of Neurology, 2009